A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
Resolutely turned towards the future thanks to the implementation of innovative techniques, the development of numerous research works and the permanent will of the teams to reach the highest level of quality, the Institut de Cancerologie de l’Ouest has become a center of excellence regional and national.
Saint-Herblain, France Clinical Trial Location
Centre Rene Gauducheau
Boulevard Professeur Jacques Monod,
44800 Saint-Herblain, France